HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting regulatory sites on proteins referred to as “natural hotspots,” today announced the close of its oversubscribed $100 million Series C financing, bringing its total funding to $190 million.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that it has closed a $52 million upsized Series B financing. The financing round was co-led by new investors H.I.G. BioHealth Partners (“H.I.G. BioHealth”) and Accelmed Partners II (“Accelmed”), with participation from Health Catalyst Capital, Revelation Partners, and a top biotechnology hedge fund, and from existing investors Sanofi Ventures, K2 HealthVentures, Hikma Ventures, and Ridgetop Health.

SPR Therapeutics, a private medical device company focused on providing patients with pain relief without opioids or surgery, announced today it has raised $37 million in an oversubscribed Series D growth equity financing. The investment will be used to accelerate the rapidly growing commercial uptake of its FDA-cleared SPRINT® Peripheral Nerve Stimulation (PNS) System, to fund additional clinical research, and to advance next generation technology.

Revelation Partners, a healthcare investment firm that provides flexible capital solutions, announced today it is expanding its team with the appointments of Dr. Doug Fisher, as Partner and Liz Staley, as Chief Compliance Officer. With over $900 million of capital under management, a rapidly growing investment portfolio, and $350 million of new capital to invest, these additions to the team will both expand the firm's technical expertise and strengthen the firm's foundation.

One Medical (1Life Healthcare, Inc., Nasdaq: ONEM), a leading human-centered and technology-powered national primary care organization, today announced it has completed the acquisition of Iora Health, a human-centered, value-based primary care organization with built-for-purpose technology focused on serving Medicare populations.

Genome Medical, the leading nationwide genomic care delivery company, today announced that it will acquire GeneMatters, a telehealth genetic counseling and software solutions company. Simultaneously, the company announced the closing of a $60 million Series C financing to accelerate commercial traction and advance its mission of transforming health care for all through genomic medicine.

Revelation Capital Management, LLC ("Revelation Partners"), a San Francisco-based investment firm focused on the healthcare sector, backed Rosetta Capital VI, LP ("Rosetta") in the acquisition of seven biotech assets from Schroder UK Public Private Trust plc ("SUPP") in an £85.0 million transaction. The closing of the acquisition occurred on March 15, 2021.

Evidation Health today announced the close of $153 million in Series E growth funding to rapidly expand its virtual health programs on AchievementTM, the largest digital health network in the United States. The round was co-led by OMERS Growth Equity and Kaiser Permanente Group Trust; existing investors, including McKesson Ventures and B Capital Group also participated.

Revelation Partners, a dedicated secondary investor in healthcare, announced the first and final closing of its newest fund, Revelation Healthcare Fund III, at its hard cap of $350 million. The oversubscribed offering surpassed the initial target of $300 million and builds on the long-term investment success of the firm.

 Syapse®, a leading real-world evidence company accelerating the delivery of precision medicine through the Syapse Learning Health NetworkTM, today announced the closing of a $68 million growth equity investment to expand Syapse’s focus on providing real-world insights to partners and assist them in improving outcomes for people with cancer. 

SetPoint Medical Corporation today announced raising $64M in a Preferred Stock Financing to support its RESET-RA pivotal trial in patients with rheumatoid arthritis (RA). The company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases and is initially focused on a potentially efficacious, yet less immunosuppressive option for the treatment of RA.

Boston Scientific Corp. said it has agreed to acquire Preventice Solutions Inc. for $925 million up front and up to an additional $300 million in a potential commercial milestone payment. The former has been an investor in Preventice since 2015 and currently holds an equity stake of about 22%, which is expected...